Immunology startup ai3Bio says it is reframing “immune reset” away from depleting pathogenic B cells and toward targeting inflammatory T cells. The company’s initial disease targets are autoimmune liver disorders with few, if any, effective treatment options. The startup’s positioning suggests a shift in the immunologic lever being pulled—moving from B-cell-centered paradigms to T-cell-driven inflammation control. For venture and partnering audiences, this indicates continued investment in immune reset, but with a specific mechanistic focus that could differentiate future assets. As ai3Bio moves from concept into preclinical and early translational validation, investors will likely watch for target selection rationale, safety strategy, and evidence of durable modulation of inflammatory T-cell states in relevant liver immune environments.